REGENXBIO Inc. Interest Expense
REGENXBIO Inc. (RGNX) reported Interest Expense of $449.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-01
- REGENXBIO Inc. interest expense for the quarter ending 2024-06-30 was $449.00K, a 59.91% decline year-over-year.
- REGENXBIO Inc. interest expense for the quarter ending 2024-03-31 was $1.97M, a 28.38% decline year-over-year.
- REGENXBIO Inc. interest expense for the quarter ending 2023-12-31 was $1.36M, a 68.38% decline year-over-year.
- REGENXBIO Inc. interest expense for the quarter ending 2023-09-30 was $1.62M, a 72.72% decline year-over-year.
- REGENXBIO Inc. interest expense for fiscal 2023 was $6.86M, a 70.49% decline from fiscal 2022.
- REGENXBIO Inc. interest expense for fiscal 2022 was $23.25M, a 11.50% decline from fiscal 2021.
- REGENXBIO Inc. interest expense for fiscal 2021 was $26.28M, a 3308.17% increase from fiscal 2020.
- REGENXBIO Inc. interest expense for fiscal 2020 was $771.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $449.00K 10-Q · filed 2024-08-01 | $2.42M 10-Q · filed 2024-08-01 | $3.79M derived: sum of 3 quarters · filed 2024-08-01 | $5.41M derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | $1.97M 10-Q · filed 2024-05-08 | $3.34M derived: sum of 2 quarters · filed 2024-05-08 | $4.96M derived: sum of 3 quarters · filed 2024-05-08 | $6.08M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.99M derived: sum of 2 quarters · filed 2024-02-27 | $4.11M derived: sum of 3 quarters · filed 2024-08-01 | $6.86M 10-K · filed 2024-02-27 |
| 2023-09-30 | $1.62M 10-Q · filed 2023-11-08 | $2.74M derived: sum of 2 quarters · filed 2024-08-01 | $5.50M 10-Q · filed 2023-11-08 | $9.81M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | $1.12M 10-Q · filed 2024-08-01 | $3.88M 10-Q · filed 2024-08-01 | $8.19M derived: sum of 3 quarters · filed 2024-08-01 | $14.14M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $2.75M 10-Q · filed 2024-05-08 | $7.07M derived: sum of 2 quarters · filed 2024-05-08 | $13.02M derived: sum of 3 quarters · filed 2024-05-08 | $19.88M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $10.26M derived: sum of 2 quarters · filed 2024-02-27 | $17.12M derived: sum of 3 quarters · filed 2024-02-27 | $23.25M 10-K · filed 2024-02-27 |
| 2022-09-30 | $5.95M 10-Q · filed 2023-11-08 | $12.81M derived: sum of 2 quarters · filed 2023-11-08 | $18.94M 10-Q · filed 2023-11-08 | $25.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $6.86M 10-Q · filed 2023-08-02 | $12.99M 10-Q · filed 2023-08-02 | $19.49M derived: sum of 3 quarters · filed 2024-02-27 | $26.20M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $6.13M 10-Q · filed 2023-05-03 | $12.63M derived: sum of 2 quarters · filed 2024-02-27 | $19.34M derived: sum of 3 quarters · filed 2024-02-27 | $25.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $13.21M derived: sum of 2 quarters · filed 2024-02-27 | $19.57M derived: sum of 3 quarters · filed 2024-02-27 | $26.28M 10-K · filed 2024-02-27 |
| 2021-09-30 | $6.71M 10-Q · filed 2022-11-03 | $13.07M derived: sum of 2 quarters · filed 2022-11-03 | $19.78M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $6.37M 10-Q · filed 2022-08-03 | $13.07M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $6.70M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $771.00K 10-K · filed 2023-02-28 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $0.00 derived: sum of 2 quarters · filed 2018-03-06 | $0.00 derived: sum of 3 quarters · filed 2018-03-06 | $20.00K 10-K · filed 2018-03-06 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $20.00K 10-Q · filed 2016-11-09 | $139.00K derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $20.00K 10-Q · filed 2016-08-09 | $139.00K derived: sum of 3 quarters · filed 2017-03-07 | $231.00K derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-03-31 | $20.00K 10-Q · filed 2016-05-05 | $139.00K derived: sum of 2 quarters · filed 2017-03-07 | $231.00K derived: sum of 3 quarters · filed 2017-03-07 | |
| 2014-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $211.00K derived: sum of 2 quarters · filed 2017-03-07 | $321.00K 10-K · filed 2017-03-07 | |
| 2014-09-30 | $92.00K 10-Q · filed 2015-11-05 | $202.00K 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | $611.00K 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |